Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

BACKGROUND: The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), disease progression and magnetic resonance imaging (MRI) activity, with a favorabl...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Miller, Aaron E, O’Connor, Paul, Wolinsky, Jerry S, Confavreux, Christian, Kappos, Ludwig, Olsson, Tomas P, Truffinet, Philippe, Wang, Lin, D’Castro, Laura, Comi, Giancarlo, Freedman, Mark S
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2012
Konular:
Research Papers
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3573676/
https://ncbi.nlm.nih.gov/pubmed/22723573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458512450354
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller